WALDENSTRÖM'S MACROGLOBULINEMIA
Clinical trials for WALDENSTRÖM'S MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM'S MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTRÖM'S MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancer: zanubrutinib trial targets untreated patients
Disease control Recruiting nowThis study tests the drug zanubrutinib (Brukinsa) in 18 Chinese adults who have Waldenström macroglobulinemia but have not yet received any treatment. The goal is to see how well the drug controls the disease and to check for side effects. Participants take zanubrutinib by mouth,…
Matched conditions: WALDENSTRÖM'S MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cancer drugs may harm hearts – study aims to find Who's at risk
Knowledge-focused Recruiting nowThis study follows 100 people taking newer BTK inhibitor drugs (acalabrutinib or zanubrutinib) for blood cancers like leukemia or lymphoma. Researchers want to see how often these drugs cause high blood pressure or heart rhythm problems, and find early warning signs. Participants…
Matched conditions: WALDENSTRÖM'S MACROGLOBULINEMIA
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Real-World study tracks Zanubrutinib's impact on blood cancer patients
Knowledge-focused Recruiting nowThis study follows 705 adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma who are taking zanubrutinib (with or without obinutuzumab). Researchers will track hospital visits, quality of life, and how well the d…
Matched conditions: WALDENSTRÖM'S MACROGLOBULINEMIA
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC